Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could umbilical cord blood help heal the womb?

NCT ID NCT07697924

Disease control Sponsor: Fundación IVI Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study investigates whether a special preparation made from umbilical cord blood, called platelet-rich plasma (hUC-PRP), can help thicken the uterine lining in women with Asherman syndrome or thin endometrium. Participants receive a single injection of hUC-PRP into the uterine wall after estrogen treatment. The goal is to see if this therapy can improve endometrial thickness, which may aid fertility.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
umbilical cord platelet-rich plasma (hUC-PRP)
What this could lead to
If effective, this therapy could offer a new way to restore the uterine lining in women with Asherman syndrome, potentially improving fertility outcomes.
What could go wrong
This is a small, early-phase study with only 35 participants, and previous results have been inconclusive. The treatment may not work for everyone, and risks include infection or procedural complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 35 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 48 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age between 18 and 48 years at the time of recruitment * body mass index (BMI): ≥ 18 kg/m2 and ≤ 35 kg/m2 * endometrial thickness \< 5 mm despite estrogen administration according to each clinic's routine practice for 10 or more days and/or evidence of Asherman syndrome. Exclusion Criteria: * Active genital infection at the time of recruitment * chronic endometritis * known endometrial pathology * psychiatric disorder that could hinder study follow-up * positive results on viral safety testing (HBsAg, HBcAb, HCV, HIV-1, HIV-2, syphilis) * presence of any syndrome or condition that, in the opinion of the principal investigator, could pose a risk to the study or to the patient * any clinically significant abnormality detected during the recruitment process * simultaneous participation in another clinical study that could affect the objectives of the present study, or prior participation in this same study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asherman syndrome are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Asherman syndrome gynatresia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asherman syndrome

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • IVI Valencia

    RECRUITING

    Valencia, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.